Abstract
For full HIV virological suppression, three fully active antiretroviral agents are required. New drug classes should be included to ensure that agents are fully active. The addition of enfuvirtide and efavirenz to the present patient’s new antiretroviral regimen ensured that two fully active agents were in use in the setting of a moderate degree of nucleoside resistance and a high level of protease resistance, and where non-nucleoside reverse transcriptase inhibitors were still fully active. Both viral load and CD4 count responded favourably to this regimen. The patient received support from physicians and clinic staff in the introduction and use of enfuvirtide. To reduce injection site reactions, a needle-free injection system (Biojector) proved effective.
Highlights
La trithérapie antirétrovirale active à base d’enfuvirtide administré à l’aide du Biojector est sûre et efficace
Three fully active antiretroviral (ARV) agents are required in an HIV treatment regimen to allow for complete virological suppression in a patient who is ARV naïve or experienced
Before initiating ARV therapy in October 1996, the patient’s CD4 count was 300 cells/mm3 (September 1996). He was initially treated with zidovudine (ZDV) and lamivudine (3TC). This treatment failed, and he was switched to a regimen of stavudine (d4T), 3TC and indinavir in March 1997
Summary
La trithérapie antirétrovirale active à base d’enfuvirtide administré à l’aide du Biojector est sûre et efficace. Three fully active antiretroviral (ARV) agents are required in an HIV treatment regimen to allow for complete virological suppression in a patient who is ARV naïve or experienced. To ensure that agents are fully active, the inclusion of ARV drugs from as many new classes as possible is important.
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call